Last updated 12 days ago
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
1050 patients around the world
Available in Costa Rica, Argentina, United States, Guatemala, Colombia, Chile, Brazil
Hoffmann-La Roche
12Research sites
1050Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Provincial del Centenario - Rosario, Santa Fe
Recruiting
Hospital Provincial del Centenario - Rosario, Santa Fe
Recruiting
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Sanatorio Parque - Rosario
Recruiting
Sanatorio Parque - Rosario
Recruiting
Centro Oncológico de Excelencia - COE San Juan
Recruiting
Centro Oncológico de Excelencia - COE San Juan
Recruiting
Sanatorio Allende (Nueva Córdoba)
Recruiting
Sanatorio Allende (Nueva Córdoba)
Recruiting
Instituto de Oncología Ángel H. Roffo - CABA, Buenos Aires
Recruiting
Instituto de Oncología Ángel H. Roffo - CABA, Buenos Aires
Recruiting
Centro Oncológico Korben
Recruiting
Centro Oncológico Korben
Recruiting
Fundación CENIT para la Investigación en Neurociencias
Recruiting
Fundación CENIT para la Investigación en Neurociencias
Recruiting
Instituto de Oncología de Rosario - IOR
Recruiting
Instituto de Oncología de Rosario - IOR
Recruiting
Hospital Alemán
Recruiting
Hospital Alemán
Recruiting
StudyPionERA
SponsorHoffmann-La Roche
Conditions
Breast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06065748
